Exploratory trial of intranasal administration of glucagon-like peptide-1 in Japanese patients with type 2 diabetes

Diabetes Care

Volumn 37, Issue 7, 2014, Pages 2024-2027

  Ueno, Hiroaki ^a   Mizuta, Masanari ^a   Shiiya, Tomomi ^a   Tsuchimochi, Wakaba ^a   Noma, Kenji ^a   Nakashima, Noboru ^b   Fujihara, Mitsuteru ^b   Nakazato, Masamitsu ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b SPG Techno Ltd Co   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 ANHYDROSORBITOL; ALBUMINOID; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLYCOALBUMIN; INSULIN; PLACEBO; UNCLASSIFIED DRUG; GLUCAGON LIKE PEPTIDE 1;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DELIVERY DEVICE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCAGON RELEASE; HUMAN; INSULIN RELEASE; INTRANASAL DRUG ADMINISTRATION; JAPANESE (PEOPLE); MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; ASIAN CONTINENTAL ANCESTRY GROUP; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; SECRETION (PROCESS);

ADMINISTRATION, INTRANASAL; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84903525487     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-0690     Document Type: Article

References (11)

1. Neumiller JJ. Incretin pharmacology: a review of the incretin effect and current incretin-based therapies. Cardiovasc Hematol Agents Med Chem 2012;10:276-288
2. Aroda VR, Ratner R. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. Diabetes Metab Res Rev 2011;27:528-542
3. Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR. Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. BMC Endocr Disord 2010;10:20
4. Illum L. Nasal drug delivery - possibilities, problems and solutions. J Control Release 2003;87:187-198 (Pubitemid 36255456)
5. Gantz I, Erondu N, Mallick M, et al. Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab 2007;92:1754-1757 (Pubitemid 46997183)
6. Fischer-Shofty M, Shamay-Tsoory SG, Harari H, Levkovitz Y. The effect of intranasal administration of oxytocin on fear recognition. Neuropsychologia 2010;48:179-184
7. Leitner VM, Guggi D, Krauland AH, et al Nasal delivery of human growth hormone: in vitro and in vivo evaluation of a thiomer/glutathione microparticulate delivery system. J Control Release 2004;100:87-95 (Pubitemid 39445988)
8. Yabe D, Watanabe K, Sugawara K, et al. Comparison of incretin immunoassays with or without plasma extraction: incretin secretion in Japanese patients with type 2 diabetes. J Diabetes Invest 2012;3:70-79
9. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995;44:1126-1131
10. Kern W, Born J, Schreiber H, Fehm HL. Central nervous system effects of intranasally administered insulin during euglycemia in men. Diabetes 1999;48:557-563 (Pubitemid 29106869)
11. Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002;5:514-516 (Pubitemid 34568991)